Attendee search 

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

The Telocyte Mission:
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer’s disease.

REM Analytics is a research and development service organisation, helping our customers develop and commercialise new products fast.
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.